Quarterly report pursuant to Section 13 or 15(d)

Revenue - Revenue from contracts with customers (Details)

v3.10.0.1
Revenue - Revenue from contracts with customers (Details)
1 Months Ended 3 Months Ended 9 Months Ended
Jan. 01, 2018
USD ($)
Sep. 30, 2018
USD ($)
customer
Sep. 30, 2018
USD ($)
customer
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
item
customer
Sep. 30, 2017
USD ($)
Disaggregation of revenue            
Total Revenue     $ 40,792,000 $ 27,185,000 $ 58,026,000 $ 33,563,000
Change in contract with customer, liability            
Deferred revenue $ 30,090,000 $ 1,345,000 1,345,000   1,345,000  
Revenue recognized in the period         1,787,000  
Changes in variable consideration     0   (10,396,000)  
Changes in percentage of completion     45,000   5,027,000  
Contract assets, liability and receivables            
Remaining performance obligation   1,345,000 1,345,000   1,345,000  
NY-ESO program            
Contract assets, liability and receivables            
Remaining performance obligation   88,000 88,000   88,000  
PRAME program            
Contract assets, liability and receivables            
Remaining performance obligation   1,257,000 1,257,000   1,257,000  
Under previous revenue guidance | ASU 2014-09            
Disaggregation of revenue            
Total Revenue     56,999,000   69,262,000  
Development revenue            
Disaggregation of revenue            
Total Revenue     1,678,000 $ 27,185,000 18,912,000 $ 33,563,000
License revenue            
Disaggregation of revenue            
Total Revenue     $ 39,114,000   $ 39,114,000  
License revenue | NY-ESO program            
Change in contract with customer, liability            
Revenue recognized in the period   $ 39,114,000        
Revenue recognized included in contract liability at beginning of the period $ 27,001,000          
GlaxoSmithKline Intellectual Property Development Ltd            
Contract assets, liability and receivables            
Number of customers | customer   1 1   1  
Number of geographic locations | item         1